证券代码：301333 证券简称：诺思格 公告编号：2024-025 诺思格（北京）医药科技股份有限公司（以下简称"公司"）根据《上市公司 独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第2号——创业板上市公司规范运作》等法律法规、规范性文 件的最新规定，并结合公司实际情况，拟对相关制度进行修订，具体如下： | 序号 | 制度名称 | 是否提交股东大会审议 | | --- | --- | --- | | 1 | 股东大会议事规则 | 是 | | 2 | 董事会议事规则 | 是 | | 3 | 独立董事工作制度 | 是 | | 4 | 关联交易管理制度 | 是 | | 5 | 对外担保制度 | 是 | | 6 | 募集资金管理办法 | 是 | | 7 | 信息披露管理办法 | 否 | | 8 | 独立董事年报工作制度 | 否 | | 9 | 董事会审计委员会工作细则 | 否 | | 10 | 董事会提名委员会工作细则 | 否 | | 11 | 董事会薪酬与考核委员会工作细则 | 否 | | 12 | 董事会战略委员会工作细则 | 否 | 上述制度的修订已经公司第四届 ...

Financial Performance - The company's revenue for Q1 2024 was ¥177,331,193.71, representing a 10.19% increase compared to ¥160,932,583.88 in the same period last year[5] - Net profit attributable to shareholders decreased by 19.95% to ¥23,048,890.81 from ¥28,792,801.97 year-on-year[5] - The company's basic earnings per share decreased by 20.00% to ¥0.24 from ¥0.30 in the same period last year[5] - Net profit for Q1 2024 was ¥23,572,914.21, a decrease of 17.6% from ¥28,678,469.89 in Q1 2023[26] - Total comprehensive income for the first quarter was CNY 23,547,386.22, a decrease from CNY 28,776,416.25 in the previous year[27] Cash Flow - The net cash flow from operating activities increased by 30.95% to ¥23,298,356.28, up from ¥17,791,127.98 in the previous year[15] - Cash inflow from operating activities totaled CNY 174,489,133.55, compared to CNY 159,186,923.75 in the previous year, reflecting a growth of 9.2%[30] - Cash outflow from operating activities was CNY 151,190,777.27, up from CNY 141,395,795.77, indicating a rise of 6.0%[30] - The company’s net cash flow from financing activities was negative CNY 9,253,748.32, worsening from negative CNY 2,884,230.04 in the previous year[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,207,965,570.12, a 6.47% increase from ¥2,073,816,068.79 at the end of the previous year[5] - The total liabilities increased to ¥431,176,262.56 from ¥319,165,864.52, reflecting a rise of 35.0%[24] - The equity attributable to shareholders rose to ¥1,774,302,419.69 from ¥1,748,411,556.50, an increase of 1.5%[24] Expenses - Management expenses rose by 77.97% to ¥27,734,313.59, primarily due to increased share-based payment amounts related to the equity incentive policy[12] - Operating costs for Q1 2024 were ¥155,064,411.27, up from ¥135,498,900.38 in the same period last year, reflecting a rise of 14.5%[25] - Research and development expenses increased to ¥14,126,228.84, compared to ¥13,570,366.43 in the previous year, marking a rise of 4.1%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,943[16] - ACE UNION HOLDING LIMITED holds 28.68% of shares, totaling 27,532,800 shares[16] - Ningbo Kaihong Venture Capital Partnership holds 12.23% of shares, totaling 11,736,000 shares[16] - Ningbo Kangyunfu Equity Investment Co., Ltd. holds 12.00% of shares, totaling 11,520,000 shares[16] - The total number of shares held by the top ten unrestricted shareholders is 40,000,000 shares[17] - The top ten shareholders do not participate in margin financing and securities lending[18] - The company’s stock ownership structure includes significant holdings by domestic private entities[16] Acquisitions and Investments - The company acquired 100% equity of Shanghai Hengling Pharmaceutical Technology Co., Ltd. in January 2024[20] - The company plans to jointly invest in an industrial fund with China International Capital Corporation[21] - The company has established a new subsidiary, increasing its investment capabilities[21] Other Financial Metrics - The company reported a significant increase in goodwill by 102,005.36% to ¥85,601,229.63 due to the acquisition of subsidiaries[10] - The weighted average return on net assets decreased to 1.31% from 1.80% year-on-year[5] - The company reported a 464.20% increase in fair value changes in profit to ¥2,881,691.79, attributed to an increase in bank wealth management products and structured deposits[12] - The company reported a decrease in other comprehensive income, with a net loss of ¥25,527.99 compared to a gain of ¥97,946.36 in the previous year[26] - Cash and cash equivalents decreased to ¥811,083,363.11 from ¥991,479,479.20, a decline of 18.2%[23] - Accounts receivable increased to ¥108,114,856.07 from ¥89,996,806.71, representing a growth of 20.1%[23]

诺思格（北京）医药科技股份有限公司 关于修订《公司章程》并办理工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 诺思格（北京）医药科技股份有限公司（以下简称"公司"）于2024年4月 19日召开第四届董事会第十九次会议，审议通过了《关于修订<公司章程>并办理 工商变更登记的议案》，该议案尚需提交公司股东大会审议。现将相关情况公告 如下： 证券代码：301333 证券简称：诺思格 公告编号：2024-024 一、《公司章程》修订情况 为进一步提升规范运作水平，完善公司治理体系，根据《公司法》《证券法》 《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证 券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》以及《上 市公司章程指引》等法律法规及规范性文件的要求，并结合公司实际情况，公司 对《公司章程》中的相关条款进行修订，具体修订内容如下： | 序号 | 修订前 | 修订后 | | --- | --- | --- | | | 第十八条 公司发起人及其认购的股份 | 第十八条 公司发起人及其认购的股份 | | | 数 ...

诺思格（北京）医药科技股份有限公司 关联交易管理制度 第一章 总 则 第五条 公司的关联人包括关联法人和关联自然人。 (一) 具有下列情形之一的法人，为公司的关联法人： 1. 直接或间接地控制公司的法人或者其他组织； 第一条 为保证诺思格（北京）医药科技股份有限公司（以下简称"公司"） 与关联方之间发生的关联交易符合公平、公正、公开的原则，确保公司关联交易 行为不损害公司和股东的利益，根据《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》（以下简称《创业板上市规则》）《深圳证券交易所上市 公司自律监管指引第 7 号——交易与关联交易》《企业会计准则第 36 号——关联 方披露》及其他有关法律、法规和规范性文件及《诺思格（北京）医药科技股份 有限公司章程》（以下简称"公司章程"）的规定，特制订本制度。 第二条 公司的关联交易是指公司或其控股子公司与关联人发生的转移 资源或义务的事项。 第三条 公司的关联交易应当遵循以下基本原则： (一) 平等、自愿、等价、有偿的原则； (二) 公平、公正、公开的原则； (三) 不损害公司及非关联股东合法权益的原则； (四) 关联股东及董事回避的原则。 第四条 公司董 ...

诺思格（北京）医药科技股份有限公司 关于公司 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301333 证券简称：诺思格 公告编号：2024-021 诺思格（北京）医药科技股份有限公司（以下简称"公司"）于2024年4月 19日召开第四届董事会第十九次会议、第三届监事会第十五次会议，审议通过了 《关于公司2023年度利润分配预案的议案》，现将具体情况公告如下： 一、利润分配预案基本情况 根据致同会计师事务所（特殊普通合伙）出具的致同审字（2024）第 110A012541号标准无保留意见的《审计报告》，2023年度母公司实现净利润为 69,186,021.80元，合并报表中归属于母公司股东的净利润为162,532,309.24元。 根据《公司法》和《公司章程》有关规定，按母公司2023年净利润的10%提取法 定盈余公积6,918,602.18元后，截止2023年12月31日，母公司累计未分配利润为 207,990,469.43元，资本公积余额为1,067,905,494.51元，合并报表累计未分配 利润为569, ...

一、出席董事会和股东大会情况 2023 年度，本人积极参加公司召开的各次会议，在会议召开前，认真阅读、 详细研究分析提交董事会审议的各项议案及相关材料。在会议上，积极参与各项 议案的讨论，对各项议案均独立负责的发表意见。本人认为公司董事会、股东大 会的召集、召开程序符合法定要求，各项重大事项均履行了相关的审批程序。 2023 年任期内，公司共召开 6 次董事会、2 次股东大会。本人亲自出席董事 会 6 次，股东大会 1 次，以谨慎的态度行使表决权，对任期内董事会的各项议案 及公司其他事项均投出赞成票，无提出异议的事项，无反对、弃权的情形，无本 人提议召开董事会的情形。 二、发表独立意见情况 诺思格（北京）医药科技股份有限公司 各位股东及股东代表： 2023 年度独立董事述职报告（李洪） 本人作为诺思格（北京）医药科技股份有限公司（以下简称"公司"）的独 立董事，在 2023 年度任职期间，严格按照《中华人民共和国公司法》《上市公司 独立董事管理办法》《上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等法律法规以及《公司章程》《独立董事议事规则》等相关制度的规定，勤 勉尽责，认真行使公司所赋予的权利 ...

诺思格（北京）医药科技股份有限公司 独立董事候选人声明与承诺 声明人孙雯，作为诺思格（北京）医药科技股份有限公司第五届董事会独 立董事候选人，现公开声明和保证，本人与该公司之间不存在任何影响本人独 立性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券 交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺 如下事项： 一、本人已经通过诺思格（北京）医药科技股份有限公司第四届董事会提 名委员会或独立董事专门会议资格审查，提名人与本人不存在利害关系或者其 他可能影响独立履职情形的密切关系。 如否，请详细说明：______________________________ 五、被提名人已经参加培训并取得证券交易所认可的相关证书。 ☑ 是 □ 否 二、本人不存在《中华人民共和国公司法》第一百四十六条等规定不得担 任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》规定的独立董事 任职资格和条件。 ☑ 是 □ 否 如否，请详细说明：________________________ ...

诺思格（北京）医药科技股份有限公司 董事会战略委员会工作细则 第一章 总 则 第一条 为了完善诺思格（北京）医药科技股份有限公司（以下简称"公 司"）的治理结构，根据《中华人民共和国公司法》、《诺思格（北京）医药科技 股份有限公司章程》（以下简称《公司章程》）及其他有关规定，公司董事会设立 专门委员会董事会战略委员会（以下简称"战略委员会"），并制定本工作细则。 第二条 战略委员会是董事会根据《公司章程》设立的专门工作机构，主要 负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第三条 战略委员会成员由 3 名董事组成，其中应至少包括 1 名独立董事。 第四条 战略委员会委员由董事长、1/2 以上独立董事或者全体董事的 1/3 以上提名，并由董事会选举产生。 第五条 战略委员会设主任委员（召集人）1 名，由公司董事长担任，负责 召集委员会会议并主持委员会工作。 第六条 战略委员会委员任期与其在董事会的任期一致，均为 3 年，委员任 期届满，连选可以连任。期间如有委员不再担任公司董事职务，自动失去委员资 格，并由董事会根据上述第三条至第五条之规定补足委员人数。 独立董事因不符合上市公司董事资格或者独立性 ...

诺思格（北京）医药科技股份有限公司 股东大会议事规则 第一章 总则 第一条 诺思格（北京）医药科技股份有限公司（以下简称"公司"）为规 范股东大会运作程序，保证股东大会合法、有序、高效地行使职权，根据《中华 人民共和国公司法》(以下简称《公司法》)等有关法律、法规及《诺思格（北京） 医药科技股份有限公司章程》（以下简称《公司章程》）的规定，并结合公司的实 际情况制订本议事规则。 第二条 本议事规则适用于公司股东大会，对公司、全体股东、股东代理人、 公司董事、监事、总经理、其他高级管理人员和列席股东大会会议的其他有关人 员均具有约束力。 第三条 公司董事会应严格遵守相关法规关于召开股东大会的各项规定，认 真、按时组织好股东大会。公司全体董事对股东大会的正常召开负有诚信责任， 不得阻碍股东大会依法行使职权。 合法、有效持有公司股份的股东均有权出席或委托代理人出席股东大会，并 依法享有知情权、发言权、质询权和表决权等各项股东权利。出席股东大会的股 东及股东代理人，应当遵守相关法规、《公司章程》及本议事规则的规定，自觉 维护会议秩序，不得侵犯其他股东的合法权益。 第四条 股东大会应当在《公司法》规定的范围内行使职权， ...

Dividend Distribution - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares to all shareholders, based on a total of 96,000,000 shares[3]. - The company announced a cash dividend of 2.00 CNY per 10 shares, totaling 19,200,000 CNY for the reporting period, which represents 100% of the distributable profit[165]. - The total distributable profit for the year was reported at 207,990,469.43 CNY[165]. Financial Performance - The company's operating revenue for 2023 reached ¥721,373,143, representing a 13.15% increase compared to ¥637,520,243 in 2022[21]. - Net profit attributable to shareholders was ¥162,532,309, a significant increase of 43.27% from ¥113,592,222 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥128,929,483, up 26.92% from ¥101,731,555 in 2022[21]. - The net cash flow from operating activities increased by 47.60% to ¥192,563,279, compared to ¥130,465,983 in 2022[21]. - Basic and diluted earnings per share rose to ¥2.08, reflecting a 50.72% increase from ¥1.39 in the previous year[21]. - Total assets at the end of 2023 amounted to ¥2,073,816,068, marking a 10.13% increase from ¥1,880,941,430 at the end of 2022[21]. - Net assets attributable to shareholders increased by 10.12% to ¥1,748,411,550 from ¥1,587,985,580 in 2022[21]. Risk Management - The report emphasizes the importance of risk awareness regarding future operational plans and performance forecasts[3]. - The company has outlined potential risks and corresponding countermeasures in the management discussion section[3]. - The company faces risks from regulatory changes in the clinical trial outsourcing business, which could affect its operational performance[93]. - The company reported a negative net profit for the last three accounting years when excluding non-recurring gains and losses, indicating ongoing uncertainty in its ability to continue as a going concern[22]. Market Expansion and Strategy - The company has a focus on expanding its market presence and developing new technologies[12]. - The company is actively involved in various investment partnerships, indicating a strategy for market expansion and collaboration[11]. - Future outlook includes continued investment in new product development and market expansion strategies to drive growth[16]. - The company plans to explore potential mergers and acquisitions to strengthen its market position and service offerings[16]. - The company is focused on expanding its innovative clinical trial technologies and global presence to enhance service offerings[53]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[128]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[140]. Research and Development - The company is currently conducting clinical trials for its innovative drugs, focusing on improving operational efficiency through AI-assisted systems[65]. - The company aims to establish a comprehensive drug detection technology system, focusing on the development of methodologies for drug detection in plasma[66]. - The R&D investment in 2023 was ¥52,863,897.11, compared to ¥49,993,012.97 in 2022, reflecting a continuous commitment to innovation[67]. - The company has invested 21.6 million in R&D, which is 57.6% of its total revenue, reflecting a strong commitment to innovation[128]. Corporate Governance - The company held 2 shareholder meetings during the reporting period, ensuring compliance with legal regulations and protecting minority shareholder rights through online voting options[106]. - The board of directors consists of 9 members, including 3 independent directors, and held 6 meetings during the reporting period, adhering to legal and regulatory requirements[108]. - The supervisory board has 3 members, including 1 employee supervisor, and convened 5 meetings, ensuring compliance with legal standards[109]. - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring transparency and alignment with the company's development[111]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a complete and autonomous business capability[114]. Employee Management - The company has established a complete and fair compensation management system, aligning employee salaries with job value and performance evaluation[161]. - The company has implemented a stock incentive plan to align employee interests with company performance[157]. - The company is focused on enhancing training effectiveness and quality to improve employee skills and overall work efficiency[162]. - The company reported a total of 2,042 employees at the end of the reporting period, with 1,903 being technical personnel, representing approximately 93.2% of the workforce[159]. Internal Control and Compliance - The company has established a comprehensive internal control system to mitigate operational risks and ensure effective governance[173]. - The internal control assurance report states that the company effectively maintained internal controls related to financial statements as of December 31, 2023[177]. - The company has not encountered any significant internal control deficiencies during the reporting period[174]. - The company emphasizes compliance with relevant laws and regulations regarding shareholder reductions to protect its interests[194]. Shareholder Commitments - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing, ensuring stability in shareholding[187]. - The company has outlined its strategy to ensure that any dividends or capital increases will be adjusted accordingly to protect the issue price[189]. - The company has established a policy to report any changes in shareholding by its executives during their tenure, promoting transparency[189]. - The company has agreed to compensate for any losses incurred due to violations of shareholding commitments, ensuring accountability[192]. Environmental Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[180]. - There were no significant environmental issues reported, and the company has not disclosed any additional environmental information[180].